• Publications
  • Influence
Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
This presentation represents consensus recommendations for the clinicopathological definition of Waldenstrom's macroglobulinemia (WM), which were prepared in conjunction with the Second International
Preclinical Studies of TW-37, a New Nonpeptidic Small-Molecule Inhibitor of Bcl-2, in Diffuse Large Cell Lymphoma Xenograft Model Reveal Drug Action on Both Bcl-2 and Mcl-1
TLDR
It is concluded that the administration of TW-37, as a potent Bcl-2 and Mcl-1 inhibitor, to standard chemotherapy may prove an effective strategy in the treatment of B-cell lymphoma.
Chromosome aberrations in a series of 120 multiple myeloma cases with abnormal karyotypes
TLDR
The results revealed that conventional cytogenetics remains an important tool in elucidating the complex and divers genetic anomalies of MM and establishes the presence of prognostic chromosomal markers such as 13/13q, 17p, 8q24, and 16q aberrations.
Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma.
TLDR
It is concluded that adding Bcl-2/Bcl-X(L) small-molecule inhibitor to standard chemotherapy may prove an effective strategy in lymphoma therapy.
Superior Antitumor Activity of SAR3419 to Rituximab in Xenograft Models for Non-Hodgkin's Lymphoma
TLDR
Overall, SAR3419 is a very active immunotoxin in preclinical models for human B- cell lymphoma and holds promise as a novel and well-tolerated therapy in B-cell non–Hodgkin's lymphoma.
Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
TLDR
This phase I study defined the maximum-tolerated dose (MTD), major toxicities, and possible antitumor activity of bryostatin 1, a macrocyclic lactone in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia and recommended phase II dose of 120 microg/m2 (40 microg-m2/d for 3 days).
The novel cyclin-dependent kinase inhibitor flavopiridol downregulates Bcl-2 and induces growth arrest and apoptosis in chronic B-cell leukemia lines.
TLDR
Results showed that flavopiridol downregulates bcl-2 mRNA and bCl-2 protein expression within 24 hours, suggesting an additional mechanism of action of this new flavone which might be useful as an agent in the treatment of chronic lymphoid malignancies.
An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals
TLDR
Overall, MI-319 probably has an anti-lymphoma potency equal to that of MI-219 and Nutlin-3, and holds the promises to be developed further for the treatment of follicular lymphoma that retains wild-type p53.
HDM2 antagonist MI-219 (spiro-oxindole), but not Nutlin-3 (cis-imidazoline), regulates p53 through enhanced HDM2 autoubiquitination and degradation in human malignant B-cell lymphomas
TLDR
A novel mechanism is suggested for MI-219 that alters the functional activity of HDM2 through enhanced autoubiquitination and degradation Additionally, this mechanism appears to correspond to biological outcome.
SMI of Bcl-2 TW-37 is active across a spectrum of B-cell tumors irrespective of their proliferative and differentiation status
TLDR
Activity of TW-37 across the spectrum of human B-cell tumors is indicated and the concept of targeting the Bcl-2 system as a therapeutic strategy regardless of the stage of B- cell differentiation is supported.
...
1
2
3
4
5
...